Lyra Therapeutics (LYRA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	25.79 mm	25.79 mm	25.79 mm	25.79 mm	25.79 mm	25.79 mm
Cash burn (monthly)	2.70 mm	37.50 k	4.15 mm	8.45 mm	5.41 mm	6.48 mm
Cash used (since last report)	10.87 mm	150.84 k	16.68 mm	33.99 mm	21.75 mm	26.05 mm
Cash remaining	14.92 mm	25.64 mm	9.11 mm	-8.20 mm	4.04 mm	-258.34 k
Runway (months of cash)	5.5	683.8	2.2	-1.0	0.7	-0.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

LYRA institutional ownership history Ownership history

68.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	67	57	+17.5%
Opened positions	20	15	+33.3%
Closed positions	10	41	-75.6%
Increased positions	13	15	-13.3%
Reduced positions	15	13	+15.4%

13F shares	Current	Prev Q	Change
Total value	8.24 bn	8.67 bn	-4.9%
Total shares	44.75 mm	48.81 mm	-8.3%
Total puts	400.00	600.00	-33.3%
Total calls	21.10 k	316.30 k	-93.3%
Total put/call ratio	0.0	0.0	+899.4%

Largest owners	Shares	Value	Change
Perceptive Advisors	12.76 mm	$3.28 bn	0.0%
NBVM GP	5.89 mm	$15.13 mm	0.0%
Citadel Advisors	4.77 mm	$1.23 bn	0.0%
Samsara BioCapital	3.28 mm	$895.00 k	+18.0%
BlackRock	2.99 mm	$769.36 mm	NEW
Samsara BioCapital	2.78 mm	$714.53 mm	0.0%
Vanguard	1.78 mm	$457.27 mm	+2.8%
Venrock Healthcare Capital Partners II	1.20 mm	$328.00 k	-78.3%
Polaris Venture Partners V	1.10 mm	$0.00	0.0%
Ikarian Capital	1.06 mm	$271.61 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Venrock Healthcare Capital Partners II	1.20 mm	-4.35 mm	-78.3%
BlackRock	2.99 mm	+2.99 mm	NEW
BLK BlackRock	0.00	-2.83 mm	EXIT
Rosalind Advisors	0.00	-1.03 mm	EXIT
SEIC SEI Investments	997.78 k	+997.78 k	NEW
Acadian Asset Management	110.49 k	-875.14 k	-88.8%
GS The Goldman Sachs Group, Inc.	547.34 k	+522.95 k	+2144.0%
Samsara BioCapital	3.28 mm	+501.51 k	+18.0%
Everhart Financial	252.71 k	+252.71 k	NEW
STT State Street	488.72 k	+228.90 k	+88.1%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LYRA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
8 Jan 25	Maria Palasis	Common Stock	Grant	Acquire A	No	No	0	800,000	0.00	1,100,000
9 Dec 24	Waksal Harlan	RSU Common Stock	Grant	Dispose A	No	No	0	128,333	0.00	0
9 Dec 24	Maria Palasis	Employee Stock Option Common Stock	Grant	Acquire A	No	No	6.07	183,333	1.11 mm	183,333
16 Oct 24	Maria Palasis	Common Stock	Grant	Acquire A	No	No	0	300,000	0.00	300,000
16 Oct 24	Jason Cavalier	Common Stock	Grant	Acquire A	No	No	0	100,000	0.00	100,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Lyra Therapeutics Q3 2024 GAAP EPS $(0.18) Beats $(0.23) Estimate, Sales $195.000K Miss $320.000K Estimate

12 Nov 24

Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. The company reported quarterly sales of $195.000 thousand which

Press releases

From Benzinga Pro

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 24

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no